Latest news with #Rallybio
Business Insider
a day ago
- Business
- Business Insider
Evercore ISI Remains a Hold on Rallybio (RLYB)
Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Rallybio on July 11 and set a price target of $1.00. The company's shares closed today at $0.42. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Sarepta Therapeutics, and ProQR. According to TipRanks, Clark-Gartner has an average return of 5.8% and a 45.07% success rate on recommended stocks. The analyst consensus on Rallybio is currently a Hold rating. The company has a one-year high of $1.54 and a one-year low of $0.22. Currently, Rallybio has an average volume of 2.8M.
Yahoo
7 days ago
- Business
- Yahoo
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of . Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news that it acquired a $25-million interest in REV102—an ENPP1 inhibitor in preclinical development for the treatment of hypophosphatasia. In a statement on Tuesday, Rallybio said it entered into a definitive agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) for the sale of its interest, under which it will be eligible to receive $7.5 million in upfront equity, a contingent equity payment of $12.5 million upon the initiation of additional preclinical studies, and a $5 million milestone payment in connection with the initiation of dosing in a Phase 1 clinical study. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. It will also be eligible to receive low single-digit royalties on all future net sales by Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) and likewise earn payments in the event of the latter's sale of the REV102 program. 'By combining Rallybio's expertise in HPP preclinical and translational research with Recursion's integrated AI/experimental platform, we transformed this concept into the first potential oral disease-modifying treatment for HPP,' said Rallybio CEO Stephen Uden. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
7 days ago
- Business
- Yahoo
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia, to joint venture partner Recursion Pharmaceuticals (RXRX) for up to $25M, including an upfront equity payment of $7.5M and near term milestones. With the upfront payment, Rallybio expects its cash runway to extend into mid-2027. The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the treatment of patients with HPP. The lead candidate from the joint venture, REV102, entered into IND-enabling studies in early 2025. Under the terms of the agreement, Rallybio is eligible to receive certain payments, including $7.5M in upfront equity, a contingent equity payment of $12.5M upon the initiation of additional preclinical studies, and a $5M milestone payment in connection with the initiation of dosing in a Phase 1 clinical study, as defined in the agreement. Rallybio is also eligible to receive low single-digit royalties on all future net sales by Recursion. In addition, Rallybio may be eligible to receive certain payments in the event of Recursion's sale of the REV102 program. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on RLYB: Disclaimer & DisclosureReport an Issue Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102 Rallybio Finalizes Employment Agreement with CMO Rallybio's FNAIT Study: A Closer Look at HPA-1a Alloimmunization Rallybio's Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk Rallybio initiates dosing in RLYB116 study Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
09-07-2025
- Business
- Business Insider
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
Rallybio (RLYB) stock rallied on Tuesday after the clinical-stage biotechnology company reached an agreement with Recursion Pharmaceuticals (RXRX). This saw Recursion Pharmaceuticals agree to acquire full interest in the two companies' joint ENPP1 inhibitor program, REV102, as well as a connected backup molecule. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. REV102 is a program designed to treat hypophosphatasia (HPP). This is a rare and debilitating genetic disorder that causes metabolic bone disease due to mutations in the ALPL gene. The issue results in a lack of alkaline phosphatase enzyme, which is needed for proper bone and tooth mineralization. Recursion Pharmaceuticals has agreed to an upfront payment of $7.5 million in equity to Rallybio, a contingent equity payment of $12.5 million when preclinical studies start, and a $5 million milestone payment when a Phase 1 trial begins. Rallybio will also receive low single-digit royalties on all future net sales by Recursion and potential payments if Recursion Pharmaceuticals sells REV102. Rallybio Stock Movement Today Rallybio stock was up 26.65% during pre-market trading on Tuesday, following a 2.31% rally yesterday. Even so, the shares have fallen 65.54% year-to-date and 73.61% over the past 12 months. Today's rally came with heavy trading, as some 34 million shares changed hands, compared to a three-month daily average of roughly 241,000 units. Is Rallybio Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Rallybio is Hold, based on three Hold ratings over the past three months. With that comes an aver age RLYB stock price target of $7, representing a potential 1,956.4% upside for the shares.
Yahoo
08-07-2025
- Business
- Yahoo
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 is commercialized. 10 stocks we like better than Recursion Pharmaceuticals › Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline. The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB). REV102 is being developed to treat hypophosphatasia (HPP) -- a rare and debilitating genetic disorder that affects bone development. According to Recursion, "HPP is a devastating genetic disorder affecting over 7,800 diagnosed patients across the U.S. and major European countries." It targets an enzyme, ENPP1, whose inhibition is believed to help treat HPP. Until today, Recursion and Rallybio have had a joint venture to develop ENPP1 inhibitors, which have resulted in REV102, still in the preclinical stage of development. The deal is good news for both companies. Focusing on Rallybio, the company will receive: Some much-needed cash in the form of $7.5 million in up-front equity An equity payment of $12.5 million if REV102 undertakes additional preclinical trials A $5 million milestone payment after initiation of dosing in a phase 1 study Low-single-digit royalties on future sales of REV102 Meanwhile, Recursion gains full ownership of REV102 and can now develop the drug without worrying about Rallybio's consideration of the matter. The agreement helps de-risk the development of REV102 and removes uncertainty around it in connection with Rallybio's financial condition. That's a plus and adds value to Recursion's pipeline, even if REV102 is in a very early stage of development. Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Here's Why Shares in Recursion Pharmaceuticals Surged Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
